Betaville

Pfizer in talks to buy Seagen Inc for more than $30 billion, reveals the Wall Street Journal

First they suggested it was Merck.

Now hacks at the Wall Street Journal claim Pfizer is in "ealy-stage" talks to buy Seagen, the US-listed biotechnology company worth more than $30 billion.

To be fair, the Wall Street Journal does report that Seagen's sale talks with Merck broke down last year.

Anyway a deal for Seagen appears to be back on. Below is a link to the WSJ scoop:..